PMPatricia Mendez

Patricia Mendez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patricia Mendez has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes

    by Marion G Peters, Man-Fung Yuen, Norah Terrault, John Fry, Pietro Lampertico, Ed Gane, Carey Hwang, Luisa M Stamm, Mitchell Leus, Mala K Maini, et al.

    Chronic hepatitis B, a major cause of liver disease and cancer, affects >250 million people worldwide. Currently there is no cure, only suppressive therapies. Efforts to develop finite curative hepatitis B virus (HBV) therapies are underway, consisting of combinations of multiple novel agents with or without nucleos(t)ide reverse-transcriptase inhibitors. The HBV Forum convened a webinar in July 2021, along with subsequent working group discussions to address how and when to stop finite therapy for demonstration of sustained off-treatment efficacy and safety responses. Participants included leading experts in academia, clinical practice, pharmaceutical companies, patient representatives, and regulatory agencies. This Viewpoints article outlines areas of consensus within our multistakeholder group for stopping finite therapies in chronic hepatitis B investigational studies, including trial design, patient selection, outcomes, biomarkers, predefined stopping criteria, predefined retreatment criteria, duration of investigational therapies, and follow-up after stopping therapy. Future research of unmet needs are discussed.


  • Open Access

    Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection

    by Adam J. Gehring, Patricia Mendez, Kirsten Richter, Hildegund Ertl, Eric F. Donaldson, Poonam Mishra, Mala Maini, Andre Boonstra, Georg Lauer, An de Creus, et al.


  • Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis

    by Jia‐Horng Kao, Donald M. Jensen, Michael P. Manns, Ira Jacobson, Hiromitsu Kumada, Joji Toyota, Jeong Heo, Boris Yoffe, William Sievert, Fernando Bessone, et al.

    Background & Aims: We compared outcomes by cirrhosis status across studies of the all‐oral combination of daclatasvir (DCV) plus asunaprevir (ASV).Methods: Outcomes from global and Japanese phase 2 and 3 clinical studies of DCV+ASV in patients with genotype (GT) 1b infection were assessed by cirrhosis status. Sustained virological response (SVR) was assessed in individual phase 3 studies; a pooled analysis was carried out for safety outcomes.Results: In the Japanese phase 3 study, SVR12 was achieved by 91% of patients with cirrhosis (n = 22) and 84% of patients without cirrhosis (n = 200); in the global phase 3 study, SVR12 was achieved by 84% of patients with cirrhosis (n = 206) and by 85% of patients without cirrhosis (n = 437). The frequency of serious adverse events, adverse events leading to treatment discontinuation and treatment‐emergent grade 3/4 laboratory abnormalities was low (n = 229) or without (n = 689) compensated cirrhosis receiving DCV+ASV. Grade 3/4 reductions in platelets and neutrophils were more common among patients with cirrhosis (1.3 and 2.2%, respectively) compared with those without cirrhosis (both 0.6%). Grade 3/4 liver function test abnormalities were less common among patients with cirrhosis (1.8%) compared with those without cirrhosis (3.5–4.7%). Alanine aminotransferase elevations were not associated with hepatic decompensation.Conclusions: The safety and efficacy of DCV+ASV were similar in patients with or without compensated cirrhosis. This all‐oral, interferon‐ and ribavirin‐free combination is an effective and well‐tolerated treatment option for patients with HCV GT1b infection and cirrhosis.Trial registrations numbers: Clinicaltrials.gov identifiers: NCT01012895; NCT01051414; NCT01581203; NCT01497834.


  • 1096 ASUNAPREVIR (ASV; BMS-650032), AN NS3 PROTEASE INHIBITOR, IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

    by J.-P. Bronowicki, S. Pol, P. Thuluvath, D. Larrey, C.T. Martorell, V.K. Rustgi, D.W. Morris, Z. Younes, M.W. Fried, M. Bourliere, et al.